The FOCUS study aims to evaluate the clinical efficacy of 0.1% cyclosporine eye drops solution (Vevizye®, Laboratoires THEA) in patients with moderate to severe dry eye disease characterized by ocular surface inflammation.
Study Type
OBSERVATIONAL
Enrollment
25
This medicinal product contains cyclosporine 0.1% as an active ingredient and pefluorobutylpentane as vehicle.
Medical University of Vienna
Vienna, Austria
Dryness score assessed by a VAS and Conjunctival hyperemia grading with Photographs (Efron) scale at week 12
Scores will be determined using a 100 mm VAS on which 0 means "no feeling of eye dryness" and 100 means "most imaginable feeling of eye dryness".
Time frame: at week 12 versus baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.